Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Quarterly Results

Quarterly Results | Annual Reports | Financial Reconciliations
2018 Quarterly Results
Q1Q2Q3Q4
Earnings Press Release
Form 10-Q
Financial Reconciliations
2017 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press ReleaseEarnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations
2016 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press ReleaseEarnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations
2015 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press ReleaseEarnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations
2014 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press Release Earnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations
2013 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press Release Earnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations
2012 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press ReleaseEarnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations
2011 Quarterly Results
Q1Q2Q3Q4
Earnings Press ReleaseEarnings Press ReleaseEarnings Press ReleaseEarnings Press Release
Form 10-QForm 10-QForm 10-QForm 10-K
Financial ReconciliationsFinancial ReconciliationsFinancial ReconciliationsFinancial Reconciliations

Stock Quote

CRL (common)
Price
$122.12
Change (%)
+ 1.70 (1.41%)
Volume
233,125
Exchange
NYSE
Data as of 07/19/18 4:00 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.

Refresh Quote

Investor Hotline

877-567-6CRL (6275)